Business Description
Quest PharmaTech Inc
NAICS : 325412
SIC : 3741
ISIN : CA74836M1068
Description
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.09 | |||||
| Equity-to-Asset | 0.98 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.4 | |||||
| 3-Year EPS without NRI Growth Rate | 17.4 | |||||
| 3-Year FCF Growth Rate | 57.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.39 | |||||
| 9-Day RSI | 65.87 | |||||
| 14-Day RSI | 62.54 | |||||
| 6-1 Month Momentum % | -54.55 | |||||
| 12-1 Month Momentum % | -70.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.26 | |||||
| Quick Ratio | 0.26 | |||||
| Cash Ratio | 0.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -1.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -28.96 | |||||
| ROA % | -28.56 | |||||
| ROIC % | -1.51 | |||||
| ROC (Joel Greenblatt) % | -23408.42 | |||||
| ROCE % | -28.94 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 0.88 | |||||
| PB Ratio | 0.09 | |||||
| Price-to-Tangible-Book | 0.09 | |||||
| EV-to-EBIT | -0.31 | |||||
| EV-to-EBITDA | -0.31 | |||||
| EV-to-FCF | -14.31 | |||||
| Price-to-Projected-FCF | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -322.58 | |||||
| FCF Yield % | -8.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quest PharmaTech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.123 | ||
| Beta | -0.5 | ||
| Volatility % | 69.97 | ||
| 14-Day RSI | 62.54 | ||
| 14-Day ATR (C$) | 0.001601 | ||
| 20-Day SMA (C$) | 0.03025 | ||
| 12-1 Month Momentum % | -70.59 | ||
| 52-Week Range (C$) | 0.02 - 0.105 | ||
| Shares Outstanding (Mil) | 169.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quest PharmaTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quest PharmaTech Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Quest PharmaTech Inc Frequently Asked Questions
What is Quest PharmaTech Inc(TSXV:QPT)'s stock price today?
The current price of TSXV:QPT is C$0.04. The 52 week high of TSXV:QPT is C$0.11 and 52 week low is C$0.02.
When is next earnings date of Quest PharmaTech Inc(TSXV:QPT)?
The next earnings date of Quest PharmaTech Inc(TSXV:QPT) is .
Does Quest PharmaTech Inc(TSXV:QPT) pay dividends? If so, how much?
Quest PharmaTech Inc(TSXV:QPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers